


Fourth Quarter 2012 Earnings Release

Agenda







☐ Dial toll—free: 855.859.2056

☐ International: 404.537.3406

☐ Conference ID: #86510532

☐ Log on to: www.idexcorp.com







Cautionary Statement Under the Private Securities Litigation Reform Act


This presentation and discussion will include forward-looking statements. Our actual performance may differ materially from that indicated or suggested by any such statements. There are a number of factors that could cause those differences, including those presented in our most recent annual report and other company filings with the SEC.




Total Revenue




EPS*



Operating Margin*



Free Cash Flow**



^{* 2012} EPS / Op Margin data adjusted for impairment charge (\$198M for Q4 and YTD) and restructuring expenses (\$18M in Q4 and \$32M YTD) while 2011 EPS / Op Margin data adjusted for restructuring expenses (\$9M in Q4 and \$12M YTD) and CVI inventory step-up expense (\$16M YTD)

IDEX Proprietary & Confidential



^{** 2011} Q4 and YTD Free Cash Flow adjusted for the forward starting interest rate swap settlement (\$39M)



Q4 Sales Mix: Organic -	1%	Q4 Summary:
Acquisition	0%	☐ Energy and Ag markets remain robust
Acquisition		☐ Chemical project activity has rebounded
Fx -:	<u>1%</u>	☐ Municipal water services remain soft
	170	☐ Excellent operational execution and productivity
Total -:	2%	☐ Improved general market environment

^{*} Op Margin data adjusted for impairment charge (2012) and restructuring expense (2012 and 2011)

IDEX Proprietary & Confidential





Q4 Sales Mix:	Organic	-3%	Q4 Summary:
	Acquisition	+9%	☐ Scientific Fluidics experienced sequential growth and favorable outlook in Asia☐ Synergies being realized between Matcon and the remainder of MPT
	Fx	<u>0%</u>	□ Optics & Photonics long term prospects remain solid □ Industrial-exposed businesses off to a good start in January 2013
	Total	+6%	

^{*} Op Margin data adjusted for impairment charge (2012), restructuring expense (2012 and 2011) and CVI inventory step-up expense (2011) IDEX Proprietary & Confidential





volume leverage

Total

IDEX Proprietary & Confidential



+9%

^{*} Op Margin data adjusted for restructuring expense (2012 and 2011)

2013 Growth Expectations

- Low to mid single digit organic revenue growth
- > Future acquisitions not contemplated in the growth below

		Sales (in Ms)	<u>EPS</u>	
FY 2012 Actuals*	\$	1,954	\$	2.68
Organic Growth		40 - 75	0.10 - 0.20	
FX		10		0.01
Full Year Acquisitions		30		0.03
Structrual Cost Benefits				0.24
Growth Investments				(0.14)
Net Inflation**				(0.07)
FY 2013 Forecast	\$2.0) - \$2.1B	\$2.85 - \$2.95	

IDEX Proprietary & Confidential

^{*} EPS adjusted to exclude impairment and restructuring charges

^{**} Wage, fringe and material inflation, net of productivity and sourcing savings

Outlook: 2013 Guidance Summary

Q1 2013

- **□** EPS estimate range: \$0.70 \$0.72
 - > Flat organic revenue growth
 - ➢ Positive acquisition impact ~ 3%
 - **→** Operating margin ~ 18.5%

FY 2013

- **□** EPS estimate range: \$2.85 \$2.95
 - > Low-to-mid single digit organic revenue growth
 - Positive acquisition impact ~ 1.5%
 - ➤ Operating margin ~ 19%
 - Positive Fx impact ~ 1% to sales
- **□** Other modeling items
 - > Tax rate ~ 29 30%
 - > Cap Ex ~ \$40 \$42M
 - > Free Cash Flow will significantly exceed net income
 - > Continued opportunistic share repurchases
 - > EPS estimate excludes future acquisitions

Q&A